Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104926 | 0.90 | NPC1 (0.44) | HSD17B1HSD17B2MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL5009603 | 0.87 | HSD17B1 (0.45) | HSD17B1HSD17B2MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL3319313 | 0.86 | HSD17B1 (0.44) | HSD17B1HSD17B2MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL3559572 | 0.85 | HSD17B1 (0.43) | HSD17B1HSD17B2MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL3093882 | 0.84 | HSD17B1 (0.43) | HSD17B1HSD17B2MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL3557513 | 0.83 | MCL1 (0.48) | MAPTSMN1; SMN2HTTMEN1ALDH1A1 | |
| SCHEMBL3100585 | 0.82 | XDH (0.39) | MAPT | |
| SCHEMBL3561731 | 0.81 | MAPK1 (0.49) | HSD17B1HSD17B2SMN1; SMN2NQO2ALDH1A1 | |
| SCHEMBL3553616 | 0.81 | MKNK1 (0.47) | MAPTGAACYP11B1CYP11B2CNR1 | |
| SCHEMBL13335627 | 0.81 | RAB9A (0.48) | MAPTSMN1; SMN2HTTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAER PHAMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | MKI67, PCNA, CCNI | HSD17B1 271/4885HSD17B2 278/4885MAPT 4163/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | HSD17B1 854/4885HSD17B2 703/4885MAPT 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.